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A FULL FACTORIAL DESIGN IN THE FORMULATION OF DIAZEPAM 
PARENTERAL NANOEMULSIONS: PHYSICOCHEMICAL 
CHARACTERIZATION AND STABILITY EVALUATION
Nebojša D. Cekić1,2, Sanela M. Đorđević3,*, Saša R. Savić1, Snežana D. Savić3                        
1Faculty of Technology, University of Niš, Leskovac, Serbia
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Using the experimental design methodology, we have developed and chara-
cterized nanoemulsions for a parenteral delivery using diazepam as a model 
drug. The formulations containing 20 or 30% (w/w) of medium chain triglyc-
erides or the mixture of medium chain triglycerides and soybean oil as the oil 
phase, soybean lecithin and polysorbate 80 as emulsifiers, and a phosphate 
buffer solution as the aqueous phase were prepared by cold high pressure ho-
mogenization. The obtained nanoemulsions were evaluated in terms of droplet 
size, size distribution, surface charge, drug–vehicle interactions and physical 
stability. To evaluate the effects of the oil phase type, oil content and drug pres-
ence, as well as their interactions on critical quality attributes of nanoemulsions, 
a three-factor two-level full factorial design was applied.
After the preparation, all nanoemulsions revealed small spherical droplets in 
the range 170–210 nm, with the narrow droplet size distribution (< 0.15) and 
the surface charge about –60 mV. The experimental design results indicated 
that not only factors alone (oil type, oil content, presence of drug), but their in-
teractions also had a significant effect on the nanoemulsion droplet size, poly-
dispersity index, and zeta potential. During two months of storage at 25 °C, all 
nanoemulsions formulated with the medium chain triglycerides–soybean oil 
mixture (4:1, w/w) remained physically stable, without considerable changes in 
monitored parameters. Physicochemical characteristics and stability of these 
nanoemulsions demonstrated their suitability for parenteral drug delivery.
Keywords: nanoemulsion; diazepam; experi-
mental design; parenteral delivery; physical sta-
bility.
Introduction 
During the last decades, there has been a renewed 
and growing interest in developing nanoemulsions as 
promising colloidal drug carriers for different routes of 
administration, especially for parenteral application. 
Considering the formulation and physicochemical chara-
cteristics, nanoemulsions have been associated with a 
number of advantages such as a low surfactant concen-
tration, a uniform and very small droplet size, low visco-
sity, and high solubilization capacity for lipophilic drugs. 
Additionally, the improved penetration through biological 
barriers, possible enhanced bioavailability and organ 
targeting could be expected with these systems [1-6]. Al-
though lipid nanoemulsions have been traditionally em-
ployed for parenteral nutrition and intravenous delivery 
of lipophilic drugs – with several approved products on 
the market – the additional efforts are required to op-
timize nanoemulsion formulation, stability, and overall 
drug delivery [1,7].
It is well known that both formulation parameters and 
processing conditions, as well as the way of the drug in-
corporation into the internal oil phase of the nanoemulsion 
may affect its physicochemical properties and stability 
[6,8-11]. In order to efficiently investigate a simultaneous 
effect of different variables that are critical for obtaining 
nanoemulsions with desired/required characteristics, a 
design of experiments approach could be a useful tool. 
However, until now only a few studies have investigated 
the influence of the formulation and/or processing fac-
tors on nanoemulsion properties and stability using this 
methodology [8,12,13].
Following such considerations, the present paper was 
aimed at formulating lecithin and polysorbate 80-contain-
ing parenteral nanoemulsions using diazepam, a lipo-
philic poorly water-soluble compound, as a model drug. 
For this purpose, placebo and drug-loaded nanoemu-
lsions were designed with the aid of experimental design, 
prepared by high pressure homogenization (HPH) and 
characterized in terms of the droplet size, size distribu-
tion, surface charge and drug–vehicle interactions. A full 
factorial experimental design was applied for the iden-
tification of the significant main and interaction effects 
of experimental factors (oil type, oil concentration and 
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the presence of drug) in order to find optimal conditions 
leading to nanoemulsions with desired physicochemical 
features. In addition, a physical stability of the obtained 
nanoemulsions during two months of storage at room 
temperature was also investigated.
Materials and methods
Materials
For the preparation of nanoemulsions, the follow-
ing ingredients were used: diazepam (DZM) (Galenika 
a.d., Serbia), medium-chain triglycerides (MCT) (Fagron 
GmbH & KG, Germany), soybean oil (SO) (Lipoid GmbH, 
Germany), soybean lecithin (Lipoid S75; Lipoid GmbH), 
polysorbate 80 (Sigma-Aldrich GmbH, Germany), butyl-
hydroxytoluene (BHT) (Sigma-Aldrich GmbH), glycerol 
(Merck KGaA, Germany), and 0.1 M phosphate buffer 
solution (PBS, pH 8). The water used in the preparation 
of formulations was double-distilled whereas ultra-pure 
water, used in analyses, was obtained with a GenPure 
apparatus (TKA Wasseranfbereitungssysteme GmbH, 
Germany). All other chemicals and reagents used were 
of pharmaceutical or HPLC grade.
Preparation of nanoemulsions
All nanoemulsions were prepared by cold HPH accord-
ing to the recently published procedure [8]. Briefly, the oil 
and the aqueous phases were separately prepared. The 
oil phase, consisting of oil (pure MCT or MCT:SO mixture 
at the mass ratio of 4:1), lipophilic emulsifier (soybean 
lecithin) and antioxidant (BHT) was heated at 70 ºC un-
der slight stirring (RH basic 2 IKAMAG® Magnetic Stirrer, 
IKA®-Werke GmbH & Co. KG, Germany), until lecithin 
was completely dissolved. The obtained oil phase was 
then allowed to cool down to the room temperature (25 ºC) 
and afterwards DZM was added and dissolved in the oil 
phase. The aqueous phase was prepared by dissolving 
hydrophilic emulsifier (polysorbate 80) in 0.1 M PBS (pH 
8). To adjust isotonicity, glycerol was added to the aque-
ous phase which was kept at 25 ºC.
The phases were combined by adding the aqueous 
phase to the oil phase, both being kept at 25 ºC, and 
further pre-homogenized with a rotor-stator homogeniz-
er IKA Ultra-Turrax® T25 digital (IKA®-Werke GmbH & 
Co. KG, Germany) at 8000 rpm for 3 min. The obtained 
coarse emulsion was subsequently homogenized with 
a high-pressure homogenizer (EmulsiFlex-C3, Aves-
tin Inc., Canada) at 500 bar for 9 repeated cycles. The 
resulting nanoemulsion was aseptically filtered through 
0.22 µm membrane filter and filled into crimped glass 
vials. Blank nanoemulsions were also prepared accord-
ing to the above procedure without DZM. All formulations 
were stored at 25 ºC and one day after preparation their 
characterization was performed. All measurements were 
done in triplicate. Code names and compositions of all 
developed nanoemulsions are given in Table 1.
Full factorial experimental design
During the nanoemulsion development, a two-level 
23 full factorial experimental design was used to identify 
and estimate the main and interaction effects of three 
different formulation factors (oil type – A, oil content – 
B, and presence of model drug – C) on critical quality 
attributes of the developed nanoemulsions. Each factor 
was varied at two coded (-1, +1) levels, in which the -1 
level corresponds to the lower value and +1 to the upper 
value of each independent variable (Table 2). Accord-
ing to the applied design, a total of eight experimental 
runs were generated and randomly performed. As the 
response variables, the nanoemulsion droplet size (Z-
Ave), polydispersity index (PDI), and zeta potential (ZP) 
were determined. The factorial design matrix and the re-
sponses of each experiment are shown in Table 3. To fit 
the experimental data, a first-order polynomial (factorial) 
model was applied (Eq. (1)):
                                                                     
                                    ............................................(1)
where Y is the measured response or dependent vari-
able, β0 is the intercept, β1, β2 and β3 are the linear coef-
ficients of the respective independent variables (A, B, C), 
and β12, β13, β23 and β123 are the interaction coefficients 
associated with respective model factor interactions (AB, 
AC, BC, ABC). The results obtained for each response 
were statistically evaluated using Design-Expert soft-
ware (Stat-Ease Inc., Minnesota, USA). A probability 
value less than 0.05 was considered to be significant. In-
teraction plots and three-dimensional response surface 
plots displaying evaluated responses (Z-Ave, PDI, ZP) at 
different factor level combinations were also constructed.
Nanoemulsion characterization
Droplet size and size distribution analysis
The mean droplet size (intensity weighted mean di-
ameter, Z-average diameter, Z-Ave) and droplet size 
distribution (polydispersity index, PDI) of nanoemulsions 
were determined by photon correlation spectroscopy 
(PCS), using a Zetasizer Nano ZS90 (Malvern Instru-
ments Ltd., UK). Before the measurement, each nanoe-
mulsion sample was diluted with freshly prepared 0.1 M 
PBS (1:500, v/v). The measurements were performed at 
25 ºC at a fixed scattering angle of 90 ºC using a He-Ne 
laser at 633 nm.
Zeta potential analysis
The droplet surface charge of nanoemulsions was 
determined using a Zetasizer Nano ZS90 (Malvern In-
struments Ltd.) by measuring the electrophoretic mobil-
ity of nanoemulsion droplets, which was converted to 
the ZP using in-built software. The measurements were 
performed at 25 ºC immediately upon the appropriate 
dilution of the samples (1:500, v/v) with the electrolyte 
solution consisting of ultra-pure water with constant con-
ductivity (about 50 μS/cm) adjusted by 0.1 M PBS.
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Electrical conductivity measurements
The electrical conductivity of all samples was deter-
mined using a CDM230 Conductivity Meter (Radiometer, 
Denmark). The measurements were performed at 25 ºC 
by direct immersion of electrode into the sample.
pH value measurements
The pH values of all nanoemulsions were determined 
using a HI9321 pH meter (Hanna Instruments Inc., Mich-
igan, USA). The measurements were performed at 25 ºC 
by direct immersion of pH meter glass electrode into the 
samples.
Differential scanning calorimetry
To evaluate the physical state of DZM in formulated 
nanoemulsions and possible interactions between the 
drug and other components, the differential scanning 
calorimetry (DSC) was performed. The DSC thermo-
grams of pure DZM, DZM-loaded and blank nanoemul-
sions were recorded using a Mettler DSC 820 apparatus 
(Mettler Toledo GmbH Analytical, Germany). The sam-
ples (about 7 mg) were accurately weighed in standard 
aluminum pans, hermetically sealed and scanned be-
tween 25 ºC and 200 ºC at a heating rate of 10 ºC/min 
under the constant nitrogen flow. An empty aluminum 
pan was used as a reference. Thermoanalytical param-
eters, such us enthalpy, onset temperature and peak 
temperature were calculated using the Mettler Toledo 
STARe software.
Fourier transform infrared spectroscopy
To investigate any chemical interaction among the in-
corporated drug and other ingredients, the Fourier trans-
form infrared (FTIR) spectroscopy was also conducted. 
The FTIR spectra of pure nanoemulsion components, 
DZM-loaded and blank nanoemulsions were obtained 
using a BOMEM Hartmann & Braun MB-Series FTIR 
spectrophotometer (ABB Bomem Inc., Canada). Prior to 
FTIR studies, the sample of the pure drug was prepared 
using the potassium bromide (KBr) pastille method. For 
the nanoemulsion sample preparation, 10 μL of nanoe-
mulsion was placed on the KRS-5 plate and dried in 
vacuum. The FTIR spectra of all samples were recorded 
between 4000 and 400 cm-1, using 10 scans for each 
spectrum, with a resolution of 4 cm-1 .
Stability study
To evaluate the physical stability of the developed na-
noemulsions, all formulations were stored at 25 °C for 
two months. The nanoemulsion Z-Ave, PDI, ZP, pH and 
electrical conductivity were determined using the previ-
ously described techniques. Statistical analysis of differ-
ences in measured parameters (one day after the pro-
duction and after two months of storage) was performed 
using Student’s t-test. The p value of 0.05 was taken as 
the level of significance.
Results and discussion
Preparation and characterization of nanoemulsions
Bearing in mind the specificity and sensitivity of par-
enteral route of administration, a special attention of the 
present investigation was paid to the selection of highly 
safe and biocompatible excipients, especially oils and 
emulsifiers, to be involved in the nanoemulsion formula-
tion. Concerning the oil phase, MCT and SO, as the most 
widely used oils in the commercially available parenteral 
lipid emulsions [1,14] were selected, whereas lecithin 
and polysorbate 80 were used as emulsifiers for the 
nanoemulsion preparation. The oil–emulsifier ratio was 
kept constant at 5:1 (w/w) in all formulations. In order to 
avoid pH alterations during storage and to keep DZM as 
a weak base in the inner oil phase, a 0.1 M PBS (pH 8) was 
chosen as the aqueous phase of the nanoemulsions.
Once the appropriate nanoemulsion components 
were chosen, a total of eight different formulations (Ta-
ble 1) concordant with the applied experimental design 
(Tables 2 and 3) were prepared using cold HPH in order 
to avoid drug crystallization and precipitation. After the 
preparation, all nanoemulsions were highly fluid and ho-
mogenous with the milky-white appearance. The results 
of representative parameters measurements (mean 
droplet size (Z-Ave), PDI, ZP) are presented in Table 3.
Table 1. Composition of nanoemulsion formulations
DZM: diazepam; MCT: medium-chain triglycerides; SO: purified soybean oil; LS75: soybean 
lecithin; BHT: butylhydroxytoluene; P80: polysorbate 80; GLIC: glycerol; PBS: 0.1 M potas-
sium phosphate buffer solution.
Table 2. Variables and levels (actual, coded) used in 23 full 
factorial design
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Table 3. Full factorial design matrix and physicochemical char-
acteristics of designed nanoemulsions one day after prepara-
tion and after two months of storage at 25 °C (mean ± SD, n=3)
n.s.: not stable (phase separation).
*Significant at p < 0.05.
For parenteral emulsions, the droplet size and size 
distribution are critical physicochemical parameters 
regarding patient safety because larger particles may 
cause embolism [2,6,15]. The mean droplet size of com-
mercial parenteral fat emulsions is usually between 100 
and 500 nm and it is generally required to be smaller 
than 1 µm [14], while the PDI, representing the size dis-
tribution width lower than 0.25 represents the acceptable 
value [16]. In the present study, the PCS particle size 
analysis (Table 3) confirmed that the mean droplet size 
(Z-Ave) of all prepared nanoemulsions was in nanome-
ter range (172–208 nm), with a relatively narrow particle 
size distribution (PDI below 0.15), suggesting that de-
veloped nanoemulsions were suitable for parenteral use.
Beside the droplet size, ZP is another important charac-
teristic of the nanoemulsions and an indicator of the na-
noemulsion stability [6,15]. Absolute ZP values greater 
than 30 mV point to good stability, while above 60 mV to 
the excellent one [16]. As Table 3 shows, all formulations 
produced revealed a negative ZP values about –60 mV, 
implying a sufficiently high negative surface charge for 
droplet-droplet repulsion and thus enhanced nanoemul-
sion stability.
Full factorial experimental design
With the purpose of gaining a better perception of how 
nanoemulsion critical properties are influenced by varia-
tions of nanoemulsion composition – type and concen-
tration of oil phase and the presence of model drug – the 
full factorial experimental design was applied in the pre-
sent study. Besides understanding the individual effect of 
the investigated factors, this design of experiments tech-
nique also allows to elucidate, with the reduced number 
of experiments, various interactions between independ-
ent variables which could not be detected with a tradi-
tional one-factor-at-a-time method [12,17,18].
Table 3 shows the results of representative responses 
measured for all nanoemulsions that were part of the 
factorial design. For each dependent variable (Z-Ave, 
PDI and ZP), the effects corresponding to the investi-
gated factors (oil phase type, oil phase content, drug 
presence) and factors interactions were calculated and 
their statistical significance was checked. Factors and 
interactions with p < 0.05 were considered significant. 
The terms with insignificant influence on estimated re-
sponses were excluded, except those required to main-
tain hierarchy, and resulting final response equations in 
terms of coded factors are given below:
                                                                         
                                                                  ..........................(2)
                                   ......................................................(3)
                                                                  ..........................(4)
The results of the statistical analysis (analysis of vari-
ance, ANOVA) showed that generated models for Z-Ave, 
PDI and ZP were significant (p < 0.05), indicating that 
three listed responses are well described by the pro-
posed models. The smaller the p value or, in other words, 
the higher the magnitude of each coefficient, the higher 
is the respective effect on the response. Experimental 
design results revealed that the mean droplet size (Z-
Ave) of nanoemulsions was significantly affected by the 
type of oil phase (A) as well as the presence of drug (C), 
with the oil type having a stronger effect. A positive sign 
for the coefficients of these model terms in Eq. (2) rep-
resented a synergistic effect on Z-Ave, meaning that the 
droplet size increased by using MCT:SO mixture as the 
oil phase and by incorporating the drug into the nanoe-
mulsion. In addition, significant interactions were identi-
fied between the oil phase type and the drug presence 
(AC) and between the oil content and the drug presence 
(BC), as presented in Figs. 1a and 2a, respectively. 
From Fig. 1a, it could be seen that when MCT:SO 
mixture was used instead of MCT, Z-Ave of blank as well 
as of DZM-loaded nanoemulsions tended to increase, ir-
respective of the oil content, and this increase was more 
pronounced in placebo nanoemulsions. Furthermore, 
Z-Ave of blank nanoemulsions formulated with MCT 
increased, whereas of DZM-loaded nanoemulsions de-
creased when the content of oil was increased from 20 
to 30% (Fig. 2b). On the contrary, when MCT:SO mixture 
was used as the oil phase, the increase of the oil content 
(from 20 to 30%) resulted in the decrease of Z-Ave for 
blank nanoemulsions, whereas the increase of Z-Ave for 
DZM-loaded nanoemulsions was observed.
From the present graphs, it can be concluded that na-
noemulsions prepared with MCT:SO were more robust 
regarding the effect of DZM on Z-Ave than those with 
MCT which appeared more sensitive to the drug pres-
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ence. Generally, it was expected that the incorporation 
of DZM into nanoemulsion would enlarge the droplet 
size, since additional lipophilic molecules need to be 
solubilized in the oil phase [1]. However, the obtained 
results also imply a possible interaction between DZM 
and emulsifier layer and, consequently, partial drug lo-
calization in the o/w interface leading to the reduction of 
the surface tension and therefore the droplet size, during 
the homogenization step [11,19].
During the model fitting procedure, it was found that 
PDI was significantly dependent on the individually test-
ed variables (A, B, and C) as well as on their combined 
effects (AC and BC). All the studied factors – the oil type, 
the oil content, and the presence of DZM – were posi-
tive, imposing a linear effect on increasing the PDI of na-
noemulsions. The results obtained from the interactions 
are shown in Figs. 1b and 2b. It can be seen that PDI 
of blank nanoemulsions increased while of DZM-loaded 
nanoemulsions decreased, when MCT:SO mixture was 
used instead of MCT as oil phase (Fig. 1b). Furthermore, 
the increase in the oil content from 20 to 30% resulted 
in the increase of PDI for blank nanoemulsions prepared 
with either pure MCT or MCT:SO mixture. Conversely, 
for DZM-loaded nanoemulsions, a decrease in PDI was 
observed (Fig. 2b).
Regarding the ZP, the oil content (B) and the drug 
presence (C) were found to be significant. The content 
of oil had a positive influence on nanoemulsion ZP (Eq. 
(4)) – the lower absolute ZP was obtained at the higher 
oil content. A negative sign for the coefficient of the drug 
presence in Eq. (4) represented an antagonistic effect 
on ZP, meaning that the surface charge of DZM-loaded 
nanoemulsions was more negative compared to unload-
ed formulations. Further, not only the investigated fac-
tors alone, but also their interactions (AB, AC, and BC) 
were shown to significantly affect the nanoemulsion ZP 
(Figs. 1c and 2c).
It could be noticed that the increase in the amount 
of oil from 20 to 30% showed the increase in absolute 
ZP of both unloaded and DZM-loaded nanoemulsions 
prepared with MCT as the oil phase. Conversely, when 
MCT:SO mixture was used, the absolute ZP of placebo 
nanoemulsion decreased, while in the DZM-loaded na-
noemulsion increased when the content of oil changed 
from 20 to 30% (Fig. 1c). Also, it is obvious that the ZP 
of placebo nanoemulsions was higher (more negative) 
and of DZM-loaded nanoemulsions lower (more posi-
tive), when MCT:SO was employed instead of pure MCT 
(Fig. 2c).
Figure1. Response surface plots showing the effects of A (oil 
phase type) and C (drug presence) on the Z-Ave (a), PDI (b), 
and ZP (c) of nanoemulsions at the middle level of B (oil con-
tent).
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Figure 2. Response surface plots for the Z-Ave (a), PDI (b), and ZP (c) of nanoemulsions as a 
function of B (oil content) and C (drug presence) at both levels of A (oil phase type).
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Drug–vehicle interactions and nanoemulsion characterization   
by DSC and FTIR
The effect of drug loading on the thermal behavior of 
the developed nanoemulsions and potential interactions 
among ingredients were examined using DSC technique. 
Fig. 3a shows DSC thermal curves obtained for the se-
lected blank and DZM-loaded nanoemulsions, as well 
as for pure DZM. The DSC thermogram of pure DZM 
showed a sharp endothermic peak at 134.28 ºC, corre-
sponding to the melting of the drug. In the DSC curves of 
both DZM-loaded and unloaded nanoemulsions, a broad 
asymmetric endothermic peak was observed around 100 ºC, 
most likely due to water evaporation. However, for DZM-
containing nanoemulsion, no melting peak of the drug 
was detected suggesting that DZM was molecularly dis-
persed in the oil phase of the nanoemulsion.
To complement the findings of the DSC, the FTIR spec-
troscopy was used as a supplementary technique for in-
vestigating intermolecular interactions in the developed 
nanoemulsion systems. Fig. 3b shows the FTIR spectra 
of blank and DZM-loaded nanoemulsions, as well as of 
pure DZM. The characteristic FTIR vibration bands ob-
served in both, DZM-loaded and blank nanoemulsion 
spectra could be directly ascribed to the features deriv-
ing from oils and lecithin. Moreover, in the FTIR profile 
of DZM-loaded nanoemulsion, the specific peaks corre-
sponding to the drug could not be detected – the DZM 
peaks disappeared or were buried in the peaks of oils. 
Also, there were no new peaks or shifts detected in this 
spectrum when compared to placebo nanoemulsion, 
confirming the absence of any chemical interaction of 
DZM with other nanoemulsion ingredients.
Figure 3. DSC thermograms (a) and FTIR spectra (b) of pure DZM, DZM-loaded (D30MS) and blank (P30MS) 
nanoemulsion.
Stability study
The physical stability of all nanoemulsions prepared 
according to the design of experiments was investigated 
after two months of storage at room temperature with re-
spect to changes in size, size distribution, surface charge, 
electrical conductivity, and pH values. Data generated 
from the stability study (Table 3) showed that the droplet 
size, PDI, and ZP – the most representative parameters 
in the control of the emulsion stability – stayed practically 
unchanged during two months of storage for all investi-
gated nanoemulsions (blank as well as DZM-loaded) for-
mulated with MCT:SO mixture as the oil phase, reflecting 
their suitability for parenteral application. On the contrary, 
the stability of all nanoemulsions produced with MCT, ex-
cept P30M, was significantly altered during the storage. 
For example, for placebo and DZM-loaded nanoemul-
sion formulations containing 20% of MCT (P20M, D20M), 
the phase separation was observed. On the other hand, 
although DZM-loaded nanoemulsion with 30% of MCT 
(D30M) did not demonstrate significant changes in Z-
Ave and PDI, free oil droplets were seen on visual in-
spection. From the results obtained, it can be suggested 
that the physical stability of nanoemulsions was possibly 
promoted by the presence of soybean oil.
The additional information about the storage stability of 
the investigated nanoemulsions was derived from the 
changes in pH and electrical conductivity over the evalu-
ated period (Fig. 4). It should be noted that the pH of 
all nanoemulsion samples slightly, but significantly de-
creased (p < 0.05) during storage. This minor drop in 
nanoemulsion pH of about 0.3–0.6 pH units could be ex-
plained by the increase in the free fatty acid content due 
to lecithin and oil hydrolytic degradation during storage. 
Concerning the electrical conductivity, a slight decrease 
was also observed, but there was no correlation be-
tween the change of this parameter and nanoemulsion 
instability. Combining all the stability parameters, we can 
conclude that currently developed nanoemulsions con-
taining the mixture of MCT and SO as the oil phase were 
more robust and more stable than those with MCT.
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Figure 4. pH values  and electrical conductivity  of nanoemulsions one day after prepara-
tion and after two months of storage at 25 °C (mean ± SD, n=3).
Conclusions
In this work, a systematic design of experiments approach 
was successfully applied to better understanding of the 
formulation of nanoemulsions as potential carriers for 
parenteral delivery of psychopharmacological drugs. 
Placebo and drug-loaded nanoemulsions stabilized by 
the lecithin/polysorbate 80 mixture and containing 20 or 
30% of the MCT or MCT:SO mixture as the oil phase, 
using DZM as a model drug were prepared by cold HPH. 
After preparation, all formulations revealed a small drop-
let size (Z-Ave about 200 nm) with the narrow droplet 
size distribution (PDI < 0.15) and ZP around –60 mV.
The results of the performed full factorial design 
showed significant main, as well as interaction effects 
of the tested factors (oil type, oil content, drug presence) 
affecting nanoemulsion critical quality attributes (Z-Ave, 
PDI, ZP). DSC and FTIR analyses indicated that DZM 
was molecularly dispersed in the investigated nanoemul-
sions, without chemical interactions with other ingredi-
ents. Based on nanoemulsion physicochemical proper-
ties and stability during 2 months of storage at 25 °C, 
developed nanoemulsions containing MCT:SO mixture 
(4:1, w/w) could be considered as promising carriers for 
parenteral drug delivery.
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PUN FAKTORSKI DIZAJN U FORMULACIJI PARENTERALNIH 
NANOEMULZIJA SA DIAZEPAMOM: FIZIČKOHEMIJSKA KARAKTERIZACIJA 
I PROCENA STABILNOSTI
Nebojša D. Cekić1,2, Sanela M. Đorđević3,*, Saša R. Savić1, Snežana D. Savić3
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Cilj ovog rada bio je da se primenom metodologije eksperimentalnog dizajna 
razviju parenteralne nanoemulzije sa diazepamom kao model lekovitom supsta-
ncom i da se sprovede njihova sveobuhvatna fizičkohemijska karakterizacija. 
Metodom homogenizacije pod visokim pritiskom na sobnoj temperaturi izrađene 
su placebo i nanoemulzije sa lekom, stabilizovane smešom lecitina i polisorbata 
80, variranjem udela i vrste uljane faze – 20 i 30% (m/m) triglicerida srednje 
dužine lanca ili smeše triglicerida srednje dužine lanca i sojinog ulja u odnosu 4:1. 
Dobijene nanoemulzije okarakterisane su u pogledu veličine i raspodele veličina 
kapi, površinskog naelektrisanja, interakcija lek–nosač i fizičke stabilnosti. U cilju 
procene istovremenog uticaja vrste uljane faze, udela ulja i prisustva leka, kao i 
njihovih interakcija, na kritične atribute kvaliteta nanoemulzija, primenjen je pun 
faktorski dizajn sa tri faktora na dva nivoa.
Nakon izrade, sve formulacije nanoemulzija imale su malu veličinu kapi u opsegu 
170–210 nm, sa veoma uskom raspodelom veličina (ispod 0,15) i površinskim 
naelektrisanjem oko –60 mV. Rezultati eksperimentalnog dizajna pokazali su da 
ne samo pojedinačni faktori (vrsta ulja, koncentracija ulja, prisustvo leka), nego i 
njihove interakcije, značajno utiču na veličinu kapi, indeks polidisperznosti i zeta 
potencijal ispitivanih nanoemulzija. Tokom 2 meseca čuvanja na 25 °C, sve na-
noemulzije formulisane sa smešom triglicerida srednje dužine lanca i sojinog ulja 
kao uljanom fazom bile su fizički stabilne, bez značajnih promena u praćenim 
parametrima. Fizičkohemijske karakteristike i stabilnost navedenih nanoemu-
lzija ukazuju da one mogu biti potencijalni nosači za parenteralnu isporuku leko-
vitih supstanci.
Ključne reči: nanoemulzija; diazepam; 
eksperimentalni dizajn; parenteralna 
isporuka; fizička stabilnost.
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